Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_4
1
17%
Ph phase_1
1
17%
Ph not_applicable
2
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 41 (20.0%)
N/A2 (40.0%)

Trials by Status

withdrawn117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

NCT05767385
completedphase_1

Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors

NCT04169321
withdrawnnot_applicable

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

NCT04941365
completednot_applicable

Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma

NCT04552964
completedphase_4

Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders

NCT04045782
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05767385Phase 2

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

Completed
NCT04169321Phase 1

Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors

Completed
NCT04941365Not Applicable

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Withdrawn
NCT04552964Not Applicable

Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma

Completed
NCT04045782Phase 4

Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders

Completed
NCT02702297

Multimodal Monitoring of Fetal Risk of Inflammation in Preterm Premature Rupture of Membranes

Completed

All 6 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
6